Fulcrum Therapeutics (FULC) Other Accumulated Expenses (2018 - 2026)
Fulcrum Therapeutics (FULC) reported Other Accumulated Expenses of $308000.0 for Q1 2026, down 30.16% year-over-year from $441000.0 in Q1 2025, and up 19.38% quarter-over-quarter from $258000.0 in Q4 2025.
Fulcrum Therapeutics (FULC) Other Accumulated Expenses (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 9 years of Other Accumulated Expenses data on file, last reported at $308000.0 in Q1 2026.
- Other Accumulated Expenses for Q1 2026 came in at $308000.0, down 30.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $308000.0 (down 30.16% YoY), and the FY2025 annual result was $258000.0, down 44.28% from the prior year.
- Other Accumulated Expenses advanced to $308000.0 in Q1 2026 per FULC's latest filing, from $258000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $463000.0 in Q4 2024 and troughed at $9000.0 in Q1 2023.
- A 5-year average of $231117.6 and a median of $258000.0 in 2025 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses sank 93.28% in 2023, then soared 4177.78% in 2024.
- A 5-year view of Other Accumulated Expenses shows it stood at $105000.0 in 2022, then surged by 277.14% to $396000.0 in 2023, then gained by 16.92% to $463000.0 in 2024, then slumped by 44.28% to $258000.0 in 2025, then gained by 19.38% to $308000.0 in 2026.
- Business Quant data shows FULC's Other Accumulated Expenses at $308000.0 in Q1 2026, $258000.0 in Q4 2025, and $236000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 308,000.00 |
| Dec 31, 2025 | 258,000.00 |
| Sep 30, 2025 | 236,000.00 |
| Jun 30, 2025 | 173,000.00 |
| Mar 31, 2025 | 441,000.00 |
| Dec 31, 2024 | 463,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 306,000.00 |
| Mar 31, 2024 | 385,000.00 |
| Dec 31, 2023 | 396,000.00 |
| Sep 30, 2023 | 265,000.00 |
| Jun 30, 2023 | 14,000.00 |
| Mar 31, 2023 | 9,000.00 |
| Dec 31, 2022 | 105,000.00 |
| Sep 30, 2022 | 25,000.00 |
| Jun 30, 2022 | 11,000.00 |
| Mar 31, 2022 | 134,000.00 |
| Dec 31, 2021 | 74,000.00 |
| Sep 30, 2021 | 57,000.00 |
| Jun 30, 2021 | 42,000.00 |